Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.

Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R.

Clin Cancer Res. 2009 Dec 15;15(24):7693-7700.

2.

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.

Sparano JA, Goldstein LJ, Davidson NE, Sledge GW Jr, Gray R.

Breast Cancer Res Treat. 2012 Jul;134(2):751-7. doi: 10.1007/s10549-012-2112-7. Epub 2012 Jun 16.

3.

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.

J Natl Cancer Inst. 2009 May 6;101(9):644-50. doi: 10.1093/jnci/djp067. Epub 2009 Apr 28.

4.

Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.

Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R.

Clin Cancer Res. 2011 Nov 15;17(22):7194-203. doi: 10.1158/1078-0432.CCR-10-3357. Epub 2011 Sep 20.

5.

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.

J Transl Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10.

6.

Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.

Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF.

J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20.

7.

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ.

J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28.

8.
9.

Adjuvant chemotherapy in early breast cancer.

Ejlertsen B.

Dan Med J. 2016 May;63(5). pii: B5222. Review.

PMID:
27127018
10.

Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.

Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct.

11.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

12.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

13.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
14.

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT.

J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212.

15.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
16.

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.

Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.

Breast Cancer Res Treat. 2012 Sep;135(2):531-7. doi: 10.1007/s10549-012-2167-5. Epub 2012 Aug 3.

PMID:
22864769
17.

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2005 Oct 20;23(30):7483-90. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.

PMID:
16234514
18.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI.

J Clin Oncol. 2015 May 20;33(15):1680-7. doi: 10.1200/JCO.2013.54.7869. Epub 2015 Apr 20.

PMID:
25897160
19.

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G.

Breast Cancer Res. 2012 Nov 12;14(6):R145. doi: 10.1186/bcr3354.

20.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2007 Dec;106(2):181-9. Epub 2007 Jan 27.

PMID:
17260090

Supplemental Content

Support Center